Names and pronunciation
(rux-oh-li′ti-nib) Jakafi
Source page 1186
Loading InternPractice…
Individual generic drug information
Extracted information for ruxolitinib only.
(rux-oh-li′ti-nib) Jakafi
Source page 1186
Func. class.: Antineoplastic agent, Janus-associated kinase inhibitor
Source page 1186
USES: Treatment of steroid-refrac- tory acute graft-versus-host disease (GVHD); treatment of intermediate or high-risk myelofibrosis including pri- mary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis; treat- ment of polycythemia vera in those with an inadequate response/hydroxyurea
Source page 1186
Extracted information for ruxolitinib only.
CONTRAINDICATIONS Hypersensitivity
Source page 1186
Black Box Warning: Fungal infection, lymphoma, MI, new primary malignancy
Source page 1186
Extracted information for ruxolitinib only.
DOSAGE AND ROUTES Graft-versus-host disease (acute; treatment), steroid-refractory • Adult: PO 5 mg bid may increase to 10 mg bid after ≥3 days of treatment (if ANC and platelets are not decreased by ≥50% compared to baseline) Myelofibrosis • Adult: PO Initial dose (based on platelet count, titrate dose thereafter based on efficacy and safety): Platelets >200,000/mm3: 20 mg bid; platelets 100,000-200,000/mm3: 15 mg bid; platelets 50,000 to <100,000/mm3 5 mg bid
Source page 1186
Available forms: Tablet 5,10,15, 20, 25 mg; topical cream 1.5%
Source page 1186
Filter the extracted dose blocks for this individual drug.
Graft-versus-host disease (acute; treatment), steroid-refractory
• Adult: PO 5 mg bid may increase to 10 mg bid after ≥3 days of treatment (if ANC and platelets are not decreased by ≥50% compared to baseline) Myelofibrosis
Candidate age grouping · source page 1186
Graft-versus-host disease (acute; treatment), steroid-refractory
• Adult: PO Initial dose (based on platelet count, titrate dose thereafter based on efficacy and safety): Platelets >200,000/mm3: 20 mg bid; platelets 100,000-200,000/mm3: 15 mg bid; platelets 50,000 to <100,000/mm3 5 mg bid
Candidate age grouping · source page 1186